{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05838729",
            "orgStudyIdInfo": {
                "id": "RiMO-HNC-IO1"
            },
            "organization": {
                "fullName": "Coordination Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer",
            "officialTitle": "Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-rimo-and-radiotherapy-with-pd-inhibitor-for-the-treatment-of-head-neck-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-13",
            "studyFirstSubmitQcDate": "2023-04-28",
            "studyFirstPostDateStruct": {
                "date": "2023-05-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-12",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Coordination Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "University of Illinois at Chicago",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.",
            "detailedDescription": "Primary Objectives:\n\n* To determine the tolerability of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab) in patients with unresectable, recurrent or metastatic head-neck cancer\n* To determine the efficacy of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab)\n\nSecondary Objectives:\n\n* To evaluate progression-free survival for up to 12 months\n* To determine overall survival for up to 24 months\n* To assess patient quality of life\n\nThe target population is patients with unresectable, recurrent or metastatic head-neck cancer which is clinically accessible to intratumoral injection."
        },
        "conditionsModule": {
            "conditions": [
                "Head Neck Cancer",
                "Intratumoral Injection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 16,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "RiMO-301",
                    "type": "EXPERIMENTAL",
                    "description": "Intratumoral injection of RiMO-301 followed by pembrolizumab or nivolumab followed by hypofractionated radiation",
                    "interventionNames": [
                        "Drug: RiMO-301"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RiMO-301",
                    "description": "A single dose of RiMO-301 will be administered via an intratumoral injection.\n\nPD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.\n\nPatients will receive hypofractionated radiation in 5 fractions.",
                    "armGroupLabels": [
                        "RiMO-301"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determination of Recommended Dose",
                    "description": "\u2022 The dose limiting toxicities of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor, as assessed by CTCAEv5, will not be observed in 33% or more patients",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Evaluation of Anti-Tumor Response",
                    "description": "\u2022 To determine the objective response rate: complete or partial response, as defined by RECIST and itRECIST",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluation of Progression-Free Survival",
                    "description": "Time from enrollment to local-regional recurrence, local-regional progression, distant progression or death from any cause, whichever occurs first",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Evaluation of Overall Survival",
                    "description": "Time from enrollment to death from any cause",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of head-neck cancer that requires palliative radiotherapy\n* Patients with unresectable, recurrent or metastatic HNSCC, regardless if the patients have progressed on or are intolerant to platinum-based chemotherapy prior to study enrollment or if the patients are receiving pembrolizumab in the first line:\n\n  * receiving a PD-1 inhibitor (pembrolizumab or nivolumab) as a standard of care, or\n  * suitable to receive a PD-1 inhibitor (pembrolizumab or nivolumab) as a standard of care in the discretion of the treating physician or Principal Investigator\n* Must have at least 1 target lesion that is clinically accessible to RiMO-301 injection and amenable to receive RT regimens specified in this protocol\n* The selected target lesions must be measurable on cross-sectional imaging and repeated measurements at the same location should be achievable\n* Target tumor not in the previously irradiated field or in the field irradiated at least six months prior to RiMO-301 injection and with no complications from the prior radiation course\n* RiMO-301 injection to multiple lesions (\u2264 5 in total) in a single patient is allowed as long as the total tumor volume does not exceed 250 cm3\n* Patient must have recovered from acute toxic effects (\u2264 grade 1 CTCAEv5) of previous cancer treatments prior to enrollment\n* Have adequate bone marrow reserve and adequate liver function\n* Have a life expectancy of at least 12 weeks\n* ECOG score of 0-2\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Have signs or symptoms of end organ failure, major chronic illnesses other than cancer, or any severe concomitant conditions\n* Symptomatic central nervous system metastases and/or carcinomatous meningitis\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* Ongoing clinically significant infection at or near the incident lesion\n* Major surgery over the target area (excluding placement of vascular access) \u226421 days from beginning of the study drug or minor surgical procedures \u22647 days. No waiting is required following implantable port, enteral feeding tube and catheter placement\n* Has received any approved or investigational anti-neoplastic agent or immunotherapy other than PD-1 inhibitors (pembrolizumab or nivolumab) within 4 weeks prior to RiMO-301 injection\n* Patients with lesions which have significant blood vessel involvement (such as carotid artery encasement) or other major structures",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ze-Qi Xu",
                    "role": "CONTACT",
                    "phone": "630-415-5601",
                    "email": "zq@coordinationpharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lawrence Feldman, MD",
                    "affiliation": "University of Illinois at Chicago",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Illinois at Chicago",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michelle Karan",
                            "role": "CONTACT",
                            "phone": "312-996-9913",
                            "email": "makaran2@uic.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "asFound": "Head Neck Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "relevance": "LOW"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}